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1. Introduction 
1.1 Alpha thalassaemia and new developments 
The thalassaemias, the commonest monogenic diseases, are a family of inherited disorders 
of haemoglobin synthesis characterised by a reduced output of one or other of the globin 
chains of adult haemoglobin. They are likely to pose an increasing health problem for many 
developing countries during the early part of the new millennium (1). This review focuses 
mainly on their control and management, a subject of increasing importance not only for 
parts of the world in which the disease is particularly common but for any country which 
has an immigrant population from these regions. 
1.2 Genetic control of haemoglobin  
All the human haemoglobins consist of two different pairs of globin chains combined with 
haemoglobin, the iron containing moiety that binds oxygen. Fetal haemoglobin, the 
synthesis of which continues throughout fetal life and declines after birth, has alpha 2-gama 
2, and in adults there is a major component called haemoglobin A (alpha 2-beta 2) and a 
minor fraction, haemoglobin A2.  
The sequence of DNA that comprises the globin genes and the chromosomal regions around 
them has been determined. Each gene consists of three coding regions (exons) and two non-
coding regions (introns). When a globin gene is transcribed, a mirror image molecule called 
messenger RNA is copied from one of the strands of DNA of the particular gene. While it is 
still in the nucleus of the red cell precursor, the intron sequences are removed and the exon 
sequences spliced together in the correct order to form the template for the production of a 
globin chain. This processed molecule moves into the cytoplasm, where it acts as the 
blueprint whereby appropriate amino acids are strung together to form a definitive globin 
chain. In adult red cells alpha and beta chains synthesised in this way combine with haem to 
form definitive haemoglobin molecules. There are also critical regulatory regions of DNA 
that are involved in ensuring that globin chains are produced in appropriate amounts in the 
correct tissues at the right time of development. The thalassaemias result from mutations or 
gene deletions that involve one or other of these complex steps. 
1.3 Definitions and classification 
The alpha and beta thalassaemias are by far the most important. In many populations in 






haemoglobins S, C, and E are also common, so it is not unusual for individuals to inherit a 
gene for thalassaemia from one parent and that for a haemoglobin variant from the other. 
The most important diseases of this type are sickle cell thalassaemia and haemoglobin E 
thalassaemia. Most of the important forms of thalassaemia are inherited in a Mendelian 
recessive fashion; carrier parents who are symptomless have a one in four chance of having 
a severely affected child. 
1.4 Population distribution 
The thalassaemias are distributed across the Mediterranean region, the Middle East, the 
Indian subcontinent, and throughout southeast Asia. In many of these countries gene 
frequencies for the different thalassaemias and structural haemoglobin variants are excess of 
alpha globin chains that are produced, and a genetically determined ability to produce high 
levels of fetal haemoglobin, are important factors (2). Heterozygotes for beta thalassaemia 
have mild hypochromic anaemia with small red cells and a raised concentration of 
haemoglobin A2. 
2. Epidemiology 
Like all common globin gene disorders (sickle cell trait and ┚ thalassaemia) alpha 
thalassaemia occurs at high frequencies throughout all tropical and subtropical regions of 
the world. In some areas, the carrier frequency of alpha thalassaemia may be as high as 80-
90% of the population, almost at fixation (3-7). It is thought that all of these globin gene 
disorders (including alpha thalassaemia) have been selected because in some way they 
protect carriers from the ravages of falciparum malaria. The micro epidemiological evidence 
supporting this is very strong (8, 9). The mechanisms underlying this protection have been 
extensively studied but remain unknown. Of all globin disorders, alpha thalassaemia is the 
most widely distributed and therefore many individuals in these areas have interacting 
combinations of these variants (e.g. both alpha and ┚ thalassaemia). Due to differences in 
the interactions between the various molecular defects underlying alpha thalassaemia HbH 
disease is predominantly seen in South East Asia, the Middle East and the Mediterranean. In 
passing it should be mentioned that ATR16, ATR-X and ATMDS syndromes show no 
geographical bias in their distributions. 
Although the previously established distribution of alpha thalassaemia, over the past few 
decades there have been massive population movements so that now the globin gene 
disorders, thought to be rarities in North European and North American clinical practice, 
have become major diagnostic and therapeutic challenges for our current health care 
systems (10). 
2.1 Screening and prevention 
The carrier states for all the important thalassaemias can be identified (11, 12) and methods 
for their prenatal diagnosis are well established. Where this approach is acceptable to 
families on religious and other grounds it is being adopted as a way of controlling 
thalassaemia. Control programmes require screening, either at the population level if the 
disease is particularly common or, more usually, at the first visit to the antenatal clinic. 
Every woman of appropriate racial background should be screened for thalassaemia by a 
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standard blood count with particular reference to the red cell indices. All the important 
carrier states for the different forms of thalassaemia are associated with a reduced mean cell 
haemoglobin concentration and cell volume. When a blood picture of this kind is 
encountered it should be followed by the estimation of the haemoglobin A2 concentration, 
which is raised in all the common forms of beta thalassaemia. It is important therefore to 
obtain the help of an expert laboratory to distinguish between these possibilities. If a mother 
is a carrier for alpha thalassaemia her pregnancy is at risk for the Bart's hydrops fetalis 
syndrome, whereas the worst possible outcome of a pregnancy involving a woman 
homozygous for alpha thalassaemia is the much milder condition, haemoglobin H disease. 
The forms of beta thalassaemia with normal haemoglobin A2 concentrations may interact 
with the other thalassaemia genes to produce a severe phenotype. 
Once a woman has been diagnosed as a carrier for one or other forms of thalassaemia her 
partner should be tested and the couple referred for expert genetic counselling. If they opt 
for prenatal diagnosis they should be referred as early as possible. 
Early prenatal diagnosis, first by fetal blood sampling and later by chorion villus biopsy and 
direct analysis of the globin genes, is now extremely effective (13). The error rate in 
experienced centres is now well under 1%, most of the mistakes resulting from either 
contamination of the fetal DNA by maternal tissue, nonpaternity, or technical problems of 
DNA analysis (14). 
Alpha thalassaemias (15, 16)  show several important differences from beta thalassaemia. 
Because alpha chains are shared by fetal and adult haemoglobin the disease is manifest in 
both fetal and adult life. Furthermore, excess gama and beta chains do not precipitate 
immediately in the bone marrow like alpha chains but produce the physiologically useless 
and unstable tetramers: haemoglobin Bart's and haemoglobin H. Since the alpha genes are 
duplicated the genetics of alpha thalassaemia is more complicated than that of beta 
thalassaemia. Usually these alpha genes are lost by deletion, though sometimes they are 
inactivated by a point mutation, as is the case in the beta thalassaemias. 
The homozygous state for alpha thalassaemia produces intrauterine death with a 
profoundly anaemic and hydropic fetus: the haemoglobin Bart's hydrops fetalis syndrome. 
Mothers carrying babies of this type commonly have toxaemia of pregnancy and post 
partum bleeding. 
Alpha thalassaemia is certainly not a rare genetic trait. On the contrary, it is one of the most 
common human genetic abnormalities known. Carriers of alpha thalassaemia are found at 
polymorphic frequency (>1%) in all tropical and subtropical populations that have been 
studied and, in some areas, the carrier state has almost gone to fixation. This is because 
carriers of alpha thalassaemia are thought to be at a selective advantage in areas where 
falciparum malaria is or has been endemic. In areas where the carrier state is common, two 
clinically important diseases (HbH disease and Hb Bart's hydrops foetalis) occur in 
compound heterozygotes and homozygotes. The reason for discussing this here is therefore 
not because these diseases are rare, rather that they may be rarely considered by physicians 
outside of the regions where thalassaemia commonly occurs. For example, a retrospective 
study of obstetric records in the U.K. by Petrou et al. revealed an underdiagnosis of both 






With the massive migrations that have occurred over the past few decades it is important to 
bring these rarely considered diseases to the general attention of clinicians in Northern 
Europe and North America. 
2.2 Disease names and synonyms 
The generic term alpha thalassaemia encompasses all of those conditions in which there is a 
deficit in the production of the alpha globin chains of haemoglobin (Hb) which is a 
tetrameric molecule including two alpha-like and two ┚-like globin chains (alpha2┚2). 
Underproduction of alpha globin chains gives rise to excess ┚-like globin chains which form 
┛4 tetramers, called Hb Bart's (in foetal life) and ┚4 tetramers, called HbH (in adult life). 
Individuals who carry mutations affecting the alpha globin genes on one chromosome, 
associated with minimal anaemia, are said to have alpha thalassaemia trait. Compound 
heterozygotes and some homozygotes for alpha thalassaemia have a moderately severe 
anaemia characterised by the presence of HbH in the peripheral blood. This condition is 
referred to as HbH disease. Finally some individuals who make very little or no alpha 
globin chains have a very severe form of anaemia which, if untreated, causes death in the 
neonatal period. This condition is called the Hb Bart's hydrops foetalis syndrome (18-21). 
Rarely patients have been seen with very large deletions which remove the alpha globin 
genes but also remove many other genes that surround them. This condition is associated 
with developmental abnormalities (including intellectual disability) and is referred to as the 
alpha thalassaemia/mental retardation syndrome on chromosome 16 (ATR16 syndrome: 
OMIM:141750, reviewed in Higgs et al., 2009 (22) and Wilkie et al., 1990 (23)). Also patients 
with a rare form of syndromal X-linked mental retardation associated with alpha 
thalassaemia have been described, in which the intellectual disability is more severe and the 
dysmorphic features show striking similarities among patients. This rare condition is called 
ATR-X syndrome and has been found to involve mutations in a chromatin associated 
protein called ATRX on the X-chromosome (ATR-X syndrome: OMIM:301040, reviewed 
elsewhere)(22, 24-27). 
Finally, an acquired form of alpha-thalassaemia referred to as the ATMDS syndrome has 
been described. This predominantly occurs in elderly males with a pre-malignant, clonal 
haematopoietic disease called myelodysplasia (MDS). This rare syndrome involves acquired 
mutations in the ATRX gene causing alpha thalassaemia (OMIM:300448, reviewed in 
Gibbons et al., 2003;Higgs et al., 2009) (22, 28). Since these rare conditions have all been 
reviewed elsewhere they will not be discussed further in this synopsis. 
2.3 Definition/diagnostic criteria 
Alpha thalassaemia is most frequently suspected initially on the basis of a routine full blood 
count. All affected individuals have a variable degree of anaemia (Hb), reduced mean 
corpuscular haemoglobin (MCH/pg), reduced mean corpuscular volume (MCV/fl) and a 
normal or slightly reduced level of the minor HbA2. These parameters are discussed in 
greater detail below. When the level of alpha globin synthesis falls below ~70% of normal, in 
the foetal period, excess ┛ globin chains form Hb Bart's which can be detected on routine Hb 
analysis (29-35). In adult life, excess ┚ globin chains form ┚4 tetramers of HbH in the cell and 
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these can be identified by staining the peripheral blood with 1% brilliant cresyl blue (BCB) 
(36-38), or when present in sufficient quantity by routine Hb analysis (36, 39). Previously 
alpha thalassaemia was confirmed by globin chain biosynthesis, when the alpha/┚ globin 
chain biosynthesis ratio was reduced to less than ~0.8 (40-44).  
All of these parameters are reduced in alpha thalassaemia but none of them alone or in 
combination can accurately or consistently predict the genotype for which directed 
molecular analysis of the alpha globin cluster is required and this is discussed below. 
2.4 Clinical description 
The clinical phenotypes of most individuals with alpha thalassaemia are very mild and may 
not be noticed during life other than when a routine full blood count is examined. Patients 
with HbH disease have a variable phenotype and those with Hb Bart's hydrops foetalis have 
a lethal form of anaemia.  
2.5 Alpha thalassaemia trait 
Apart from mild to moderate microcytic hypochromic anaemia (detected on a routine blood 
count), carriers (heterozygotes) of alpha thalassaemia, whatever the molecular basis (see 
below), are clinically asymptomatic and the diagnosis (when made) is often established 
during a regular health check or during antenatal screening. Complaints related to more 
severe anaemias, such as fatigue, listlessness and shortness of breath are uncommon and 
almost certainly related to other concomitant disorders. 
Carriers of alpha+- or alpha0-thalassaemia alleles generally do not need treatment, because 
their anaemia is either very mild or absent due to a compensating high red blood cell count. 
On the other hand, once a diagnosis of alpha thalassaemia trait is made, there is a tendency 
to discard iron-deficiency as a subsequent cause of anaemia. Carriers of alpha thalassaemia 
can be anaemic as a consequence of coexisting nutritional deficiencies, such as iron 
deficiency, folate or vitamin B12 deficiencies and should be managed correctly from this 
point of view. Of course prophylactic iron should never be given to carriers of alpha 
thalassaemia who are at risk of developing iron overload if treated inappropriately. 
2.6 Genotype/phenotype correlations 
Although there are now 128 different molecular defects known to cause alpha thalassaemia 
and an ever increasing number of potential interactions, the clinical phenotypes (broadly 
classified as alpha thalassaemia trait, HbH disease and Hb Bart's hydrops foetalis) resulting 
from the interactions between these various molecular defects. The severity of the clinical 
phenotype correlates very well with the degree of alpha globin chain deficiency. An 
important additional point is that, in general, interactions involving non-deletional forms of 
alpha+-thalassaemia result in a more severe phenotype than in those with deletional forms 
of alpha+-thalassaemia (45-59). 
2.7 Diagnosis and diagnostic methods 
Initial laboratory testing should include a complete blood count with red cell indices, HPLC 






The latter procedure, however, is sometimes by passed by DNA analysis as a less 
complicated method to diagnose alpha-thalassaemia. 
2.8 Molecular analysis 
Over the past 30 years it has become increasingly possible to diagnose alpha thalassaemia 
accurately and define the precise defects underlying these disorders using a variety of 
molecular genetic approaches. Ultimately, most alpha globin rearrangements have been 
characterised by Southern blotting and DNA sequence analysis. However, for today's 
diagnostic demands these techniques are far too laborious to apply in each case, and from 
the original work defining these mutations, rapid screening assays have been developed. 
2.9 Differential diagnosis 
Sometimes carriers of alpha+-thalassaemia present with normal haematology, especially 
carriers of –alpha 3.7 and non deletional mutations affecting the alpha1-gene. Such 
individuals may be normocytic or borderline hypochromic without anaemia. These can only 
be found by chance during routine molecular analysis for haemoglobinopathies. 
2.10 Prognosis 
There is no reason to think that carriers for alpha thalassaemia have any altered prognosis 
for life compared to the normal population. The prognosis for patients with HbH disease 
who are newly emerging in previously nonendemic countries, like Northern Europe and 
Northern America, is less clear. Anecdotally many patients with HbH disease appear to lead 
a normal life in all respects. Some even remain undiagnosed throughout their lives. 
However, detailed actuarial studies are not available. When complications arise, of course 
the outcome depends on the awareness and availability of health care systems. Certainly 
some complications suffered by patients with HbH disease are life threatening in the 
absence of adequate medical care (21, 60, 61). A long term problem for all patients with HbH 
disease is the unwanted accumulation of iron which may be more of a problem for those 
with severe HbH disease with nondeletional alpha- thalassaemia (62, 63). 
Clearly, previously undiagnosed and untreated infants with the Hb Bart's hydrops foetalis 
syndrome die in the perinatal period. The recent attempts to rescue infants with this 
syndrome either by intra-uterine transfusion or by transfusion in the perinatal period have 
met with variable success. As discussed above many infants develop other irreversible 
abnormalities during foetal life and even with rescue the infant will be required, either to 
receive lifelong blood transfusion and iron chelation therapy, or bone marrow 
transplantation  with its attendant risks. 
3. Therapy and management of Alpha-thalassemia 
Alpha-thalassemia silent carrier and alpha-thalassemia trait:  
Alpha globin is made by four genes, two on each strand of chromosome 16. Individuals who 
have one or two abnormal alpha globin genes have alpha thalassemia trait. An individual 
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which one of the four alpha globin genes is missing or defective, generally causes no health 
problems because the lack of alpha globin protein is so small that there is no anemia. It is 
called "silent carrier" because of how difficult it is to detect. Silent carrier state is "diagnosed" 
by deduction when an apparently normal individual has a child with hemoglobin H disease 
or alpha thalassemia minor. It can also be diagnosed by special DNA testing.  
Hb H disease:  
Hemoglobin H disease is an inherited hemoglobin disorder in which three of the four alpha 
globin genes normally present are deleted or have a mutation which impairs alpha globin 
chain production. This leads to an excess of beta globin chains, which are unstable, 
precipitate within the cell and lead to destruction of the red blood cells. Hemoglobin H is a 
thalassemia-like syndrome characterized by hemolysis as well as ineffective red cell 
production. Co-inheritance of HbH with other globin gene defects can affect the severity of 
the condition. Hemoglobin H disease has a wide spectrum of clinical severity in patients, 
therefore, early diagnosis is important so patients can be followed. Hemoglobin levels and 
the patient’s growth and development should be regularly monitored. Complications 
related to chronic hemolysis also need to be assessed. Infections should to be monitored 
closely so any severe drop in hemoglobin can be recognized and treated. Health care 
monitoring and maintenance with appropriate immunizations are important as well. 
Hb Bart hydrops fetalis:  
Hydrops fetalis is a serious disorder, usually indicative of an ominous prognosis for the 
affected fetus. There are many causes, including both hereditary and acquired diseases. 
With population migrations during the past decades, this syndrome is now seen in 
increasing numbers in other parts of the world. Hydrops fetalis can be diagnosed and 
monitored by ultrasound scans. Prenatal ultrasound scanning enables early recognition of 
hydrops fetalis and has been enhanced with the introduction of MCA Doppler. Recent 
advances in molecular genetics have provided insights into the mutations and 
pathophysiology causing ┙-thalassemias, as well as definitive clinical diagnostic tests for 
adult carrier detection and prenatal diagnosis. Severely anemic fetuses can be treated with 
blood transfusions while still in the womb. 
4. Future expectations in Alpha thalassaemia 
Alpha thalassemia severity ranges from asymptomatic to fatal in utero. Hemoglobin H 
disease, a mutation of three alpha globin genes, is more severe than previously recognized. 
New developments in the epidemiology, treatment and prognosis of thalassemia have 
dramatically altered the approach to the care of affected patients, and these developments 
are likely to have an even greater impact in the next few years. Alpha thalassemia is being 
recognized with increasing frequency in Turkey, and newborn screening for Hemoglobin 
Barts in some states is leading to early detection of Hb H disease. New data clarify the 
importance of distinguishing these two disorders because of the increased severity 
associated with Hb H. The use of intrauterine transfusions to sustain the viability of fetuses 
with homozygous alpha thalassemia has created a new population of patients with severe 
thalassemia and has raised new and complex issues in genetic counseling for parents with 






understanding of the unique features of alpha thalassemia disorders that were previously 
uncommon in Turkey but are now seen more frequently in children and recognized more 
consistently in adults. Anemia, hypersplenism, hemosiderosis, growth failure, and 
osteoporosis are commonly noted as the patient ages. Alpha thalassemia major, a usually 
fatal in utero disease, is now recognized to have a complex molecular and phenotypic 
expression with increasing births being reported. Surviving newborns without intrauterine 
transfusion often have congenital anomalies and neurocognitive injury. Serious maternal 
complications often accompany pregnancy. Doppler ultrasonography with intrauterine 
transfusion ameliorates these complications. The high incidence in many populations 
mandates population screening and prenatal diagnosis of at-risk couples. Universal 
newborn screening has been adopted in several regions with DNA confirmatory testing. 
These advances have resulted in ethical dilemmas for the family and the provider. 
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